glp-1 roche reveals first data with Carmot-sourced oral drug Roche Bets Splits in Obesity

The theoretical benefits of low-dose GLP-1 therapy for inflammation include the potential for anti-inflammatory effects with a reduced side effect burden compared to standard doses

These agents are derived from either exendin or human GLP-1 and are designed to have enhanced enzymatic stability against dipeptidyl peptidase 4 (DPP-4), along with slower elimination kinetics compared to native GLP-1

GLP-1s have been used for diabetes treatment since 2005 and for weight management since 2014

Global, regional, and national burden of chronic kidney disease, 19902017: a systematic analysis for the global burden of disease study 2017

Obesogenic Neighborhood Environments, Child and Parent Obesity: The Neighborhood Impact on Kids Study

The FDA advisory on GLP-1s specifically mentions medullary thyroid cancer